Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2025 Q2 Revenue: USD 16.41 M

Revenue: As of FY2025 Q2, the actual value is USD 16.41 M.

EPS: As of FY2025 Q2, the actual value is USD 0.45.

Cash and Cash Equivalents

• As of June 30, 2025, Fortress Biotech’s consolidated cash and cash equivalents totaled $74.4 million, an increase of $17.1 million from $57.3 million as of December 31, 2024.

Segment Revenue

• Journey Medical’s net product revenues for the second quarter ended June 30, 2025, were $15.0 million, compared to $14.9 million for the same period in 2024.
• Fortress Biotech’s consolidated net revenue totaled $16.4 million for the second quarter ended June 30, 2025, compared to $14.9 million for the second quarter of 2024.

Operational Metrics

• Consolidated research and development expenses were $8.1 million for the second quarter ended June 30, 2025, compared to $12.7 million for the same period in 2024.
• Consolidated selling, general and administrative costs were $38.8 million for the second quarter ended June 30, 2025, compared to $20.8 million for the same period in 2024.
• Consolidated net income attributable to common stockholders was $13.4 million, or $0.50 per share basic, and $0.45 per share diluted, for the second quarter ended June 30, 2025, compared to a net loss of - $13.3 million, or - $0.73 per share basic and diluted, for the second quarter ended June 30, 2024.

Outlook / Guidance

• Fortress Biotech anticipates the PDUFA goal date for CUTX-101 on September 30, 2025, and the potential issuance of a Priority Review Voucher upon approval.
• The company plans to advance MB-101, in combination with MB-108, as a potential treatment option for high-grade gliomas.
• Journey Medical continues to expand payer coverage for Emrosi™, now reaching 65% of U.S. commercial lives.